Structure Therapeutics Q3 loss widens to $145M
The company expects its $1.2 billion cash position as of September 30, 2026 to fund clinical milestones through 2028, excluding pre-commercialization costs.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Structure Therapeutics Inc. reported third-quarter 2026 results and clinical updates, including a $144.8 million net loss compared with $65.7 million in the third quarter of 2025. Research and development expense was $134.6 million versus $59.0 million, while general and administrative expense was $21.8 million versus $14.8 million.
Cash, cash equivalents and short-term investments totaled $1.2 billion as of September 30, 2026. The company expects that balance to fund projected operations and key clinical milestones through the end of 2028, including aleniglipron’s Phase 3 program, but excluding additional pre-commercialization costs such as commercial manufacturing. The ACCOMPLISH-1 and ACCOMPLISH-2 Phase 3 trials are enrolling, with topline data expected in the second half of 2028.
For aleniglipron, the company reported up to 16.2% mean body-weight reduction at 72 weeks in the highest-dose group in the ACCESS extension. ACCG-2671’s multiple-ascending-dose study is dosing, with topline results expected in the first half of 2027; its single-dose study showed an approximately six-day half-life and no serious adverse events.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- None.
Negative
- Moderate pointThird-quarter net loss was $144.8 million, compared with $65.7 million in 2025.
8-K Event Classification
Key Figures
Key Terms
single ascending dose medical
multiple ascending dose medical
pharmacokinetics medical
open-label extension medical
registrational clinical trials medical
Earnings Snapshot
The company expects cash, cash equivalents and short-term investments of $1.2 billion as of September 30, 2026 to fund projected operations and key clinical milestones through the end of 2028, excluding additional pre-commercialization costs including commercial manufacturing.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Structure Therapeutics’ Q3 2026 financial results?
What is Structure Therapeutics studying in the ACCG-2671 multiple-dose trial?
What additional aleniglipron data does Structure Therapeutics expect in Q4 2026?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State
or other jurisdiction |
(Commission |
(IRS Employer |
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s
telephone number, including area code): (
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange On Which Registered | ||
| Global Market | ||||
| Global Market* |
* Not for trading, but only in connection with the registration of the American Depositary Shares
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition.
On November 9, 2026, Structure Therapeutics Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the third quarter ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit | ||
| No. | Description | |
| 99.1 | Press Release dated November 9, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Structure Therapeutics Inc. | ||
| Date: November 9, 2026 | By: | /s/ Raymond Stevens |
| Raymond Stevens, Ph.D. | ||
Chief Executive Officer | ||
Exhibit 99.1
Structure Therapeutics Reports Third Quarter
2026 Financial Results
and Recent Highlights
Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational
clinical trials of
aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling;
topline data expected in 2H 2028
Additional aleniglipron data expected in Q4
2026
from supplementary body composition, type 2 diabetes and SWITCH studies
Reported Phase 1 SAD data for ACCG-2671 (oral
small molecule amylin receptor agonist),
demonstrating a ~6-day half-life and no serious adverse events;
MAD clinical trial dosing underway, with topline data expected in 1H 2027
Cash, cash equivalents and short-term investments
of $1.2 billion as of September 30, 2026
expected to fund projected operations and key clinical milestones through 2028
SAN FRANCISCO, November 9, 2026 (GLOBE NEWSWIRE) – Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the third quarter ended September 30, 2026, and provided a business update across its oral small molecule obesity portfolio.
“With our Phase 3 ACCOMPLISH program underway, we are advancing aleniglipron toward potential registration while building a broader portfolio of differentiated oral small molecule treatments for chronic weight management,” said Raymond Stevens, Ph.D., Chief Executive Officer of Structure Therapeutics. “We are developing our commercial readiness plans and see significant opportunity for aleniglipron in both initial weight loss and long-term weight loss maintenance.”
Dr. Stevens continued, “We are also advancing our oral small molecule amylin portfolio by progressing the multiple ascending dose clinical trial of ACCG-2671, preparing to initiate a Phase 1 clinical trial of ACCG-3535 and exploring GLP-1 combination approaches. Our strategy is to develop differentiated monotherapy and combination medicines to address a range of patient needs. We believe convenient oral administration and scalable manufacturing could help expand access to these potential treatments globally.”
Recent and Upcoming Milestones
Aleniglipron – Oral Small Molecule Selective Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist
The Phase 3 ACCOMPLISH program, which initiated in August 2026, comprises two randomized, double-blind, placebo-controlled clinical trials designed to evaluate the long-term efficacy and safety of aleniglipron and to support global regulatory submissions for chronic weight management.
| · | ACCOMPLISH-1 is enrolling up to 3,600 adults living with obesity or overweight with at least one weight-related comorbidity. ACCOMPLISH-2 is enrolling up to 1,100 adults living with obesity or overweight and type 2 diabetes mellitus (T2DM). |
| · | In both trials, participants will receive placebo or one of three aleniglipron maintenance doses (45 mg, 90 mg or 180 mg) following a 2.5 mg starting dose and dose escalation at four-week intervals. Topline data are expected in the second half of 2028. |
In September 2026, the Company reported 72-week results from the ACCESS open-label extension (OLE), a prespecified 36-week extension of the Phase 2b ACCESS clinical trial designed to evaluate the longer-term safety and tolerability of aleniglipron and the durability of weight loss through 72 weeks of treatment. Participants originally randomized to the 45 mg, 90 mg and 120 mg arms in ACCESS who continued into the OLE dosed up to 180 mg. Data demonstrated up to 16.2% mean reduction in body weight in the highest dose group at 72 weeks with no observed plateau in the two top dose groups, and improved tolerability with a 2.5 mg starting dose, including treatment discontinuation rates of less than 5% due to treatment-emergent adverse events.
The Company will present two posters on aleniglipron at The Obesity Society’s Annual Meeting, ObesityWeek® 2026, taking place November 14–17, 2026, in National Harbor, Maryland. The presentations will cover the ACCESS OLE and the dose-ranging effects of aleniglipron across the ACCESS trials. Both posters are scheduled for presentation on November 15, 2026.
Additional aleniglipron data expected in the fourth quarter of 2026 include topline results from three supplementary clinical trials designed to build on the Phase 2 findings and further characterize aleniglipron’s clinical profile:
| · | Body composition clinical trial: Results from a 44-week study evaluating the effects of aleniglipron on body fat and overall body composition. |
| · | T2DM clinical trial: Results from a 30-week study in adults living with T2DM and obesity or overweight. |
| · | SWITCH clinical trial: Results evaluating the transition from an approved injectable GLP-1 receptor agonist to once-daily oral aleniglipron for weight loss maintenance. This study assesses different aleniglipron starting doses and weight loss maintenance over 12 weeks. |
Oral Small Molecule Dual Amylin and Calcitonin Receptor Agonists
In September 2026, the Company reported topline results from the single ascending dose (SAD) portion of its Phase 1/2a clinical trial of ACCG-2671, an oral small molecule dual amylin and calcitonin receptor agonist (DACRA). The SAD portion evaluated the safety, tolerability, pharmacokinetics (PK) and exploratory pharmacodynamics of single doses of 1, 2, 5 or 10 mg of ACCG-2671 or placebo in 31 healthy adult participants without obesity. ACCG-2671 demonstrated a half-life of approximately 6 days. No serious adverse events were reported.
The Company has begun dosing in the 12-week multiple ascending dose (MAD) portion of the Phase 1/2a trial, a randomized, placebo-controlled study evaluating the safety, tolerability and PK of multiple ascending oral doses of ACCG-2671 administered for 84 days across multiple cohorts of participants living with obesity. The trial will evaluate daily and weekly dosing regimens and different titration approaches. It also includes a cohort evaluating ACCG-2671 added to a stable dose of an injectable GLP-1 receptor agonist. Topline data from the MAD portion are expected in the first half of 2027.
The Company plans to initiate a Phase 1 clinical trial of its second oral small molecule DACRA candidate, ACCG-3535, in the fourth quarter of 2026.
In addition, the Company expects to initiate a clinical trial evaluating a combination of an oral small molecule amylin and GLP-1 receptor agonists in 2027.
Third Quarter 2026 Financial Highlights
Cash Position: Cash, cash equivalents and short-term investments totaled $1.2 billion as of September 30, 2026, compared to $1.3 billion as of June 30, 2026. The Company expects its current cash, cash equivalents and short-term investments to fund projected operations and key clinical milestones through the end of 2028, including costs related to the Phase 3 registrational program for aleniglipron in chronic weight management, but excludes additional costs related to pre-commercialization activities including commercial manufacturing.
Research and Development (R&D) Expenses: R&D expenses for the third quarter of 2026 were $134.6 million, as compared to $59.0 million for the same period in 2025. The increase in R&D expenses was primarily due to increases related to clinical trial costs, preclinical research and development expenses, and employee expenses.
General and Administrative (G&A) Expenses: G&A expenses for the third quarter of 2026 were $21.8 million, as compared to $14.8 million for the same period in 2025. The increase in G&A expenses was primarily due to increases in employee expenses as the Company expanded its infrastructure to drive and support the growth in operations.
Net Loss: Net loss for the third quarter of 2026 totaled $144.8 million, with non-cash share-based compensation expense of $12.7 million, compared to a net loss of $65.7 million for the same period in 2025, with non-cash share-based compensation expense of $7.5 million.
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next-generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release are statements that could be deemed forward-looking statements, including, without limitation, statements concerning: the Company’s future plans and prospects, including its research and development activities; the design, initiation, enrollment, conduct, timing and completion of the Company’s clinical trials, including the aleniglipron Phase 3 ACCOMPLISH program, the ACCG-2671 MAD clinical trial, the ACCG-3535 Phase 1 clinical trial and the combination amylin/GLP-1 clinical trial; and the timing of topline, interim or additional data readouts from the aleniglipron Phase 3 ACCOMPLISH program, the ACCG-2671 MAD clinical trial and the aleniglipron body composition, SWITCH and type 2 diabetes clinical trials; the belief that convenient oral administration and scalable manufacturing could help expand access; the Company’s expectation that the aleniglipron ACCOMPLISH clinical trials will support regulatory submissions for aleniglipron in chronic weight management; any expectations regarding the potential benefits, tolerability and safety profile, accessibility, scalability, combinability, capability, efficacy, convenience, expected effects, competitive positioning (including any characterization of a product candidate as potential “best-in-class” or “first-in-class”) and future application of aleniglipron, ACCG-2671, ACCG-3535 and any of the Company’s other investigational compounds; the Company’s ability to support global regulatory submissions for its product candidates and to obtain, maintain and expand regulatory approvals; and the Company’s expectations regarding its cash, cash equivalents and short-term investments and its estimated cash runway, including its ability to fund projected operations and clinical milestones through the end of 2028. In addition, when or if used in this press release, the words and phrases “continue,” “could,” “anticipated,” “believe,” “expect,” “may,” “on track,” “plan,” “potential,” “project,” “remain,” “target,” “suggests,” “to be,” “to begin,” “will,” and similar expressions and their variants, as they relate to the Company, may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation: the risk that topline, interim or preliminary data the Company reports are based on a preliminary analysis of then-available efficacy and safety data, and such data may change following a more comprehensive review of the data related to the applicable clinical trial, and such topline, interim or preliminary data may not accurately reflect the complete or final results of a clinical trial; the preliminary nature of clinical results given the length of the applicable clinical trial and sample size, and the fact that results from earlier clinical trials are not necessarily predictive of future results; potential delays in the commencement, enrollment, conduct or completion of the Company’s planned and ongoing clinical trials, including the Phase 3 ACCOMPLISH program; the risk that clinical trial results may not support further development or regulatory approval of aleniglipron, ACCG-2671, ACCG-3535, or the Company’s other therapeutic candidates; the Company’s ability to obtain and maintain regulatory approval of, and ultimately successfully commercialize, its therapeutic candidates; the effect of competitive products or therapeutic approaches on the commercial value of the Company’s product candidates; the Company’s ability to fund its development activities and achieve its development goals; and other risks and uncertainties described in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Quarterly Report on Form 10-Q, and other reports the Company has filed or may file with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investors:
Corey Davis, Ph.D., LifeSci Advisors, LLC, 212-915-2577, cdavis@lifesciadvisors.com
Jen Robinson, Structure Therapeutics Inc., ir@structuretx.com
Media:
Dan Budwick, 1AB, Dan@1abmedia.com
STRUCTURE THERAPEUTICS INC.
Condensed Consolidated Statements of Operations
(unaudited)
(In thousands)
| THREE MONTHS ENDED | NINE MONTHS ENDED | |||||||||||||||
| SEPTEMBER 30, | SEPTEMBER 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 134,552 | $ | 58,989 | $ | 301,116 | $ | 156,566 | ||||||||
| General and administrative | 21,781 | 14,798 | 63,226 | 43,983 | ||||||||||||
| Total operating expenses | 156,333 | 73,787 | 364,342 | 200,549 | ||||||||||||
| Loss from operations | (156,333 | ) | (73,787 | ) | (364,342 | ) | (200,549 | ) | ||||||||
| Interest and other income, net | 11,747 | 8,183 | 38,053 | 26,688 | ||||||||||||
| Loss before provision for income taxes | (144,586 | ) | (65,604 | ) | (326,289 | ) | (173,861 | ) | ||||||||
| Provision for income taxes | 171 | 108 | 595 | 345 | ||||||||||||
| Net loss | $ | (144,757 | ) | $ | (65,712 | ) | $ | (326,884 | ) | $ | (174,206 | ) | ||||
STRUCTURE THERAPEUTICS INC.
Condensed Consolidated Balance Sheet Data
(unaudited)
(In thousands)
| SEPTEMBER 30, | DECEMBER 31, | |||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash, cash equivalents and short-term investments | $ | 1,239,975 | $ | 1,446,197 | ||||
| Prepaid expenses and other current assets | 35,151 | 124,106 | ||||||
| Total current assets | 1,275,126 | 1,570,303 | ||||||
| Property and equipment, net | 10,262 | 6,653 | ||||||
| Operating right-of-use assets | 6,576 | 6,245 | ||||||
| Other non-current assets | 42,455 | 717 | ||||||
| Total assets | $ | 1,334,419 | $ | 1,583,918 | ||||
| Liabilities and shareholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 33,878 | $ | 13,864 | ||||
| Accrued expenses and other current liabilities | 70,463 | 46,543 | ||||||
| Operating lease liabilities, current portion | 2,763 | 2,878 | ||||||
| Total current liabilities | 107,104 | 63,285 | ||||||
| Operating lease liabilities, net of current portion | 4,065 | 3,609 | ||||||
| Other non-current liabilities | 1,380 | 647 | ||||||
| Total liabilities | 112,549 | 67,541 | ||||||
| Total shareholders’ equity | 1,221,870 | 1,516,377 | ||||||
| Total liabilities and shareholders’ equity | $ | 1,334,419 | $ | 1,583,918 | ||||